RecruitingPhase 2NCT07179055
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
An Eight-Week, Double-Masked, Randomized, Placebo-Controlled, Phase 2, Evaluation of the Safety and Efficacy of VSJ-110 Ophthalmic Solution in the Treatment of Dry Eye
Sponsor
Vanda Pharmaceuticals
Enrollment
160 participants
Start Date
Oct 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Be at least 18 years of age of either gender and any race.
- Provide written informed consent and sign the HIPAA form.
- Be willing and able to follow all instructions and attend all study visits.
Exclusion Criteria1
- Use of any of the disallowed medications during the washout and study period.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGVSJ-110
ophthalmic solution
DRUGPlacebo
ophthalmic solution
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07179055
Related Trials
Effect of Dry Eye Treatment on Corneal Astigmatism Measurements
NCT076578581 location
The Effect of Rinsing on Ocular Inflammation and Symptoms in Patients With Dry Eye Disease
NCT076183641 location
Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment
NCT076066251 location
A Study to Evaluate the Performance and Safety of Artelac® Complete MDO® Versus VISMED® MULTI Eye Drops in the Management of Moderate to Severe Dry Eye Disease
NCT075938855 locations
Comparative Assessment of Lipid Layer Thickness Measurements
NCT075791301 location